Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:ACTIRiib antagonists

Discover how Acceleron Pharma's patent for treating spinal muscular atrophy with ALK4:ActRIIB antagonists aims to increase muscle mass, strength, and bone density in patients.

Related Posts

Mankind Pharma acquires Bharat Serums and Vaccines for ...

Jul 28, 2024

Two genomics powerhouses team up to expand infectious d...

Jan 26, 2024

Ascendis Pharma files patent for ocular drug delivery s...

Mar 24, 2024